- Home
- CMBM vs TVGN Comparison
CMBM vs TVGN Comparison
Compare CMBM & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMBM | TVGN |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Blank Checks |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.5M | 63.9M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CMBM | TVGN |
|---|---|---|
| Price | $1.54 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 355.4K | ★ 751.1K |
| Earning Date | 02-19-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $172,215,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.01 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $0.28 |
| 52 Week High | $6.80 | $1.69 |
Technical Indicators
Market Signals| Indicator | CMBM | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.35 | 37.54 |
| Support Level | $1.52 | $0.32 |
| Resistance Level | $1.68 | $0.36 |
| Average True Range (ATR) | 0.13 | 0.03 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 35.53 | 23.68 |
Price Performance
Historical ComparisonAbout CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.
About TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.